Literature DB >> 28337665

Effect of Efflux Transporter Inhibition on the Distribution of Fluconazole in the Rat Brain.

Wei Wang1, Na Zheng1, Jiatang Zhang2, Xusheng Huang1, Shengyuan Yu1.   

Abstract

Multidrug resistance-associated proteins (MRPs) and organic anion transporters (OATs) are expressed on the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB), preventing the entry of or the pumping out of numerous molecules. Fluconazole is widely used to treat fungal meningoencephalitis. The effect of these transporters on the distribution of fluconazole in the brain is unclear. We used microdialysis to compare the distribution of fluconazole in the rat brain with and without co-administration of probenecid, a MRP and OAT inhibitor. Additionally, we also observed the difference in fluconazole distribution between the two barriers. The results showed that probenecid increased the penetration of fluconazole into the BBB but did not alter the penetration of fluconazole into the BCSFB of rats. The penetration of the BBB and BCSFB by fluconazole did not statistically differ according to physiological condition. These results demonstrate that transporters that can be inhibited by probenecid may be involved in fluconazole resistance at the BBB and provide a laboratory basis for predicting brain extracellular fluid (ECF) concentration using the cerebrospinal fluid (CSF) concentration of fluconazole.

Entities:  

Keywords:  Blood-brain barrier (BBB); Blood-cerebrospinal fluid barrier (BCSFB); Fluconazole; Multidrug resistance-associated proteins (MRPs); Organic anion transporters (OATs); Probenecid

Mesh:

Substances:

Year:  2017        PMID: 28337665     DOI: 10.1007/s11064-017-2240-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  32 in total

1.  Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals.

Authors:  P F Watson; M E Rose; S W Ellis; H England; S L Kelly
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

Review 2.  CNS pharmacokinetics of antifungal agents.

Authors:  Shravan Kethireddy; David Andes
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-08       Impact factor: 4.481

3.  Dose-dependent pharmacokinetics of probenecid in the rat.

Authors:  B M Emanuelsson; L K Paalzow
Journal:  Biopharm Drug Dispos       Date:  1988 Jan-Feb       Impact factor: 1.627

4.  Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis.

Authors:  H Yang; Q Wang; W F Elmquist
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

5.  Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system.

Authors:  Y Deguchi; K Nozawa; S Yamada; Y Yokoyama; R Kimura
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

6.  Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase.

Authors:  Alia A Sagatova; Mikhail V Keniya; Rajni K Wilson; Brian C Monk; Joel D A Tyndall
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

7.  Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats.

Authors:  Heidrun Potschka; Steffen Baltes; Wolfgang Löscher
Journal:  Epilepsy Res       Date:  2004-02       Impact factor: 3.045

8.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats.

Authors:  Francine Johansson Azeredo; Bibiana Verlindo de Araújo; Sandra Elisa Haas; Bruna Torres; Maiara Pigatto; Cristiane de Andrade; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

10.  Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1.

Authors:  Cuicui Wang; Zhen Hong; Yinghui Chen
Journal:  Neurochem Res       Date:  2015-06-20       Impact factor: 3.996

View more
  1 in total

1.  Population Pharmacokinetic Modeling to Describe the Total Plasma and Free Brain Levels of Fluconazole in Healthy and Cryptococcus neoformans Infected Rats: How Does the Infection Impact the Drug's Levels on Biophase?

Authors:  Izabel Almeida Alves; Keli Jaqueline Staudt; Fernando Olinto Carreño; Graziela de Araujo Lock; Carolina de Miranda Silva; Stela Maris Kuze Rates; Teresa Dalla Costa; Bibiana Verlindo De Araujo
Journal:  Pharm Res       Date:  2018-04-27       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.